Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility



Status:Active, not recruiting
Conditions:Hospital, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases, Other
Healthy:No
Age Range:18 - Any
Updated:2/28/2019
Start Date:July 2015
End Date:April 2020

Use our guide to learn which trials are right for you!

A Phase 2, Multicenter, Open-label Study to Measure the Safety of Extending Preservation and Assessment Time of Donor Lungs Using Normothermic Ex Vivo Lung Perfusion and Ventilation (EVLP) as Administered by the SPONSOR Using the Toronto EVLP System™

This is a safety study to compare the safety of receiving a lung treated with the Toronto
EVLP System™ by SPONSOR in SPONSOR's dedicated facility against standard lung
transplantation.

Human donor lungs allocated to a participating study transplant center (Study Center) for a
specific recipient and meeting study EVLP donor lung inclusion/exclusion criteria will be
assessed by SPONSOR for inclusion into the study.

Upon retrieval, donor lung(s) will be packaged and transported on ice to the SPONSOR's EVLP
facility in Silver Spring, Maryland, no differently than when lungs are recovered, packaged,
and transported to any transplant center for implantation.

The EVLP procedure will be performed by Certified Ex Vivo Lung Specialists using the Toronto
EVLP System™ for up to 6 hours, collecting and relaying lung function assessment data hourly
or as requested by the Study Center transplant surgeon. Additionally, the Study Center
surgeon will have the capability to evaluate lung function data and monitor the procedure
remotely through a dedicated video link.

Upon acceptance of an EVLP donor lung by the Study Center, the single lung or lung block is
cooled down by the Toronto EVLP System™ to 10 degrees C. Thereafter, perfusion and
ventilation are stopped and the lung is prepared for hypothermic storage and transport to the
accepting Study Center.

Subject Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the
following criteria:

- Male or female patients

- All patients, 18 years of age or older

- Patient already on or added to the active waiting list for a single or bilateral lung
transplant

- Patient or patient's representative provides informed consent for participation in the
study at the time of study commencement or time of listing for transplant

- Patient or patient's representative reconfirms informed consent for the study on the
day of lung transplant

Subject Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from participation:

- Patients listed for same-side lung re-transplantation

- Patients listed for multiple organ transplantation including lung and any other organ

- Patients listed for live donor lobar transplant

- Patients with HIV, active Hepatitis B/C, or Burkholderia Cepacia

- Patients not initially consented into the study prior to the time of lung transplant

- Patients in the ICU at the time of initial lung offer requiring mechanical
ventilation, ECMO or other Extracorporeal life support (ECLS).

Donor Lung Inclusion Criteria for EVLP Assessment:

The donor lung must meet at least one of the following criteria to proceed with EVLP:

- At the time of the clinical evaluation, the donor PaO2/FiO2 < 300 mmHg

- Donor received ≥ 10 units of blood transfusions

- Donation after Cardiac Death (DCD) donor

- Expected cold ischemic time > 6 hours

- Donor age ≥ 55 years old

- Study Center Investigator requires additional assessment ex vivo and/or extended
preservation time

Donor Lung Exclusion Criteria for EVLP Assessment:

The donor lung is excluded from EVLP if at least one of the following criteria have been
met:

- The donor lung has confirmed pneumonia and/or persistent purulent secretions
identified via bronchoscopy

- Non-persistent purulent secretions that do not clear by hour 3 on EVLP

- The donor lung has confirmed evidence of aspiration

- The donor lung has significant mechanical lung injury or trauma

- The cold ischemic time, starting at donor aortic cross clamp/ initial flush (CIT-1),
required to transport the lung from the donor site to start of the EVLP procedure at
SPONSOR's facility > 10 hours

EVLP Lung Inclusion Criteria for Transplantation:

The donor lung must meet each of the following conditions post-EVLP for transplant
suitability consideration by the Study Center Investigator:

- PvO2/FiO2 ≥ 350 mmHg at final EVLP evaluation time period

- and < 15% increase from baseline value (defined as the first hour collection point) to
final value of pulmonary vascular resistance (PVR)

- and < 15% increase from baseline value to final value of peak airway pressure (PawP)

- and < 15% decrease from baseline value to final value of static lung compliance
(Cstat)

- and the total preservation time (TPT) does not exceed the following:

- the initial CIT-1 time from donor to EVLP > 1 hour and ≤ 10 hours

- the EVLP time > 3 hours and ≤ 6 hours

- the second CIT-2 from EVLP cool down to beginning of recipient implantation must
be > 1 hour and ≤ 6 hours for the first lung

- the second CIT-2 from EVLP cool down to beginning of recipient implantation must
be > 1 hour and ≤ 10 hours for the second lung

- and Study Center Investigator deems lung function suitable for intended subject

EVLP Lung Exclusion Criteria for Transplantation:

The donor lung is excluded from transplant inclusion if at least one of the following
criteria have been met:

- PvO2/FiO2 < 350 mmHg at final EVLP evaluation time period

- or ≥ 15% increase from baseline value to final value of pulmonary vascular resistance
(PVR)

- or ≥ 15% increase from baseline value to final value of peak airway pressure (PawP)

- or ≥ 15% decrease from baseline value to final value of static lung compliance (Cstat)

- or TPT exceeds any of the following conditions:

- CIT-1 < 1 hour or > 10 hours

- EVLP < 3 hours or > 6 hours

- CIT-2 < 1 hour or > 6 hours for first lung or > 10 hours for second lung

- or Study Center investigator deems lung function unsuitable for intended subject
We found this trial at
8
sites
22 S Greene St
Baltimore, Maryland 21201
(410) 328-8667
Phone: 410-328-3822
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Phone: 216-445-9303
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
(734) 936-4000
Phone: 734-763-5785
University of Michigan Health System The University of Michigan is home to one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Chicago, Illinois 60141
Phone: 708-216-5404
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Durham, North Carolina
Phone: 919-613-5653
?
mi
from
Durham, NC
Click here to add this to my saved trials
Falls Church, Virginia 22042
Phone: 703-776-6147
?
mi
from
Falls Church, VA
Click here to add this to my saved trials
Jacksonville, Florida 32216
Phone: 904-956-3271
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Phone: 412-647-8323
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials